# Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer

> **NCT00614601** · PHASE2 · TERMINATED · sponsor: **NewLink Genetics Corporation** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** HyperAcute(R)-Pancreatic Cancer Vaccine

## Key facts

- **NCT ID:** NCT00614601
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2010-05
- **Final completion:** 2014-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Sponsor proceeded with a phase III study for same indication.
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00614601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00614601, "Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00614601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*